Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2010

View Archived Issues

BNC-210 is well tolerated in healthy volunteers

AZ-004 is efficacious in preclinical model of inflammatory pain

Rivaroxaban is as effective as standard therapy in treating deep vein thrombosis

Oral JNJ-41876666 is active against cold allodynia in models of neuropathic pain

New glucagon receptor antagonists claimed by Merck & Co.

Abbott presents new inhibitors of GlyT-1

Shionogi recaps Q1 highlights of fiscal year 2010

New alpha2C-adrenoceptor agonists display antinociceptive effects and cardiovascular safety in vivo

Patient enrollment complete in Antisoma's phase III trial of AS-1413

BMS acquires ZymoGenetics and PEG-interleukin-29 for HCV infection

Transgene and Jennerex enter into exclusive partnership for JX-594

Sylentis to begin new phase I/II trial of SYL-040012 for elevated IOP and glaucoma

NeuroSearch discloses new voltage-gated potassium channel activators

GSK presents new dual histamine H1/H3 receptor antagonists

Merck & Co. discontinues development of MK-6913 for hot flashes

Taisho Pharmaceutical claims new selective SGLT1 inhibitors

N30 Pharma begins dosing in first-in-human phase I trial of N-6022

FDA advisory committee recommends approval of ceftaroline fosamil for CABP and cSSSI

Cempra begins studies of oral and intravenous solithromycin

Phase III trial begins of oral methylnaltrexone in opioid-induced constipation

FDA approves expanded indications for Saphris

Condition for approval removed for Avastin in Japan

Mylan acquires Bioniche Pharma ahead of schedule

Emergent BioSolutions begins phase I trial of inhalational anthrax treatment

FDA approves Abbott RealTime HBV assay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...